EICHORCondition: Acute Myeloid Leukemia · Sponsor: Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Interested? Contact the study team ↓
The purpose of this study is to estimate the efficacy of immunotherapy with ex vivo expanded haploidentical NK cells for children/young adults with primary high risk or refractory AML and relapsed AML.
This description comes directly from the study's public registry record.
Tatsiana Shman, PhD · +375296341853 · shman@oncology.by
Mariya Naumovich, MD · +375293563846 · mariyanaumovich@gmail.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: Patients: * primary high risk AML * primary refractory AML * relapsed AML * Karnofsky or Lansky performance scale greater or equal to 70 * written informed consent Donors: * haploidentical family donor * donor suitable for cell donation and apheresis according to standard criteria * written informed consent Exclusion Criteria: Patients: * uncontrolled infection * severe hepatic dysfunction: SGOT or SCPT \>=5x upper limit of normal for age * positive serology for human immunodeficiency virus (HIV) Donors: * pregnancy * positive serology for HIV, hepatitis B or C
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Belarussian Research Center for Pediatric Oncology, Hematology and Immunology | Minsk, Minsk Oblast, Belarus | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05272293